The shortened time of trastuzumab was more likely to influence the cancer relapse in patients receiving more aggressive chemotherapy such as anthracycline and taxane-containing regimen (β = 0.06, P = 0.037), as well as in those with hormone receptor-positive disease (β = 0.06, P = 0.021). The gene discussed is NR4A1; the disease is cancer.